Mercado Global de Síndrome de Lennox Gastaut – Tendências do setor e previsão para 2030

Análise e dimensão do mercado da síndrome de Lennox Gastaut

A pandemia em curso está a alterar consideravelmente a dinâmica do sector farmacêutico e da saúde. Vários hospitais, centros de atendimento cirúrgico ambulatório e clínicas em todo o mundo estão a adotar dispositivos e equipamentos avançados. O crescimento da receita do mercado da Síndrome de Lennox Gastaut é consideravelmente impulsionado por fatores como o aumento da prevalência de doenças crónicas, os rápidos avanços na saúde e no setor médico.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado da síndrome de Lennox Gastaut no período de previsão 2023-2030. O mercado esperado da síndrome de Lennox Gastaut CAGR tende a rondar os 4,60% no período de previsão mencionado. O mercado foi avaliado em 700 milhões de dólares em 2022 e cresceria até 1.003,12 milhões de dólares até 2030. Para além dos insights de mercado, como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes do mercado e o cenário de mercado, o O relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui também uma análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado da síndrome de Lennox Gastaut

Market Definition

Lennox-Gastaut syndrome (LGS) also known as pediatric epilepsy syndrome or childhood epileptic encephalopathy. It is usually characterized by mental retardation, reduced intellectual powder, multiple tonic-clonic seizures and strange findings on electroencephalography. It is most frequently observed between second and sixth year of the life.

Lennox Gastaut Syndrome Market Dynamics

Drivers

• Prevalence of Lennox-Gastaut Syndrome

According to National Organization for Rare Disease, around 1%-4 % of all cases of infantile epilepsy are caused by Lennox-Gastaut syndrome, which affects 0.1-0.28 people out of every 100,000 people. In addition to this, out of 100,000 children, 2 are thought to be affected by lennox-gastaut syndrome every year, whichcommonly appears between ages  2 to 7, with a peak onset between ages  3 and 5.

• Increasing Awareness About Lennox Gastaut Syndrome

The rising awareness about the diseased condition is spreading much awareness about the diagnosis and treatment of the same. Numerous governmental and non-governmental organizations such as Genetic and Rare Diseases (GARD) Information Center, Epilepsy Society, Genetic Alliance Australia, National Organization of Rare Disorders (NORD) are educating people and providing medical care and support to LGS patients. These organizations are raising awareness about the symptoms, diagnosis, signs, and treatment of LGS

Opportunities

• Rising Demand Of  Non-Surgical Treatment

The non-surgical treatment segment resulted in the highest Lennox-Gastaut syndrome treatment market share due to the recent LGS drug approvals and the higher adoption of ketogenic diet. Thus, this is creating much awareness about the market growth.

• Emergence of New Varied Treatments

Several companies are primarily focusing on the development of minimally invasive procedures such as MR-guided laser interstitial thermal therapy (MRg-LITT). MRg-LITT has become a safe, effective, and durable alternative to traditional open corpus callosotomy. The accurate efficacy of MRg-LITT is also being tested in advanced surgical ablation of epileptogenic foci and corpus callosotomy.

Restraints/Challenges

• Lack of Awareness

For many decades, epilepsy and seizures related disorders have been enveloped in discrimination, stigma, misinformation, and fear, in several parts of the world. The quality of life of people are used to be compromised due to disease's societal stigma, that still exists in many modern-day countries. The stigma connected with ailment may discourage some people from seeking treatment as they don't want to be identified with it.

• High Cost of Treatment Process

The huge expenditure required for its treatment processes impedes the market growth. Several market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.

This  Lennox Gastaut syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Lennox Gastaut syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Lennox Gastaut Syndrome Market Scope

The Lennox Gastaut syndrome market is segmented on the basis of symptoms, route of administration, end-user distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Symptoms

• Medication
• Surgery
• Intravenous Immunoglobulin Therapy
• Ketogenic Diet Products

Route of Administration

• Oral
• Parenteral

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Lennox Gastaut Syndrome Market Regional Analysis/Insights

The Lennox Gastaut syndrome market is analyzed and market size insights and trends are provided by symptoms, route of administration, end-user distribution channel as referenced above.

The major countries covered in the Lennox Gastaut syndrome market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

A América do Norte domina o mercado devido às elevadas atividades de investigação e desenvolvimento na área da neurologia e à forte presença das indústrias farmacêuticas.

Considera-se que a Ásia-Pacífico irá crescer nos próximos anos devido ao aumento da sensibilização, à infraestrutura de cuidados de saúde bem estabelecida e ao aumento das despesas com a saúde.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país. 

Cenário competitivo e análise global da quota de mercado da síndrome de Lennox Gastaut

O panorama competitivo do mercado da síndrome de Lennox Gastaut fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado da síndrome de Lennox Gastaut

Os principais players que trabalham no mercado Síndrome de Lennox Gastaut incluem:

• Novartis AG (Suíça)
• F. Hoffmann-La Roche Ltd (Suíça)
• (EUA)
• Bayer AG (Alemanha)
• Empresa Bristol Myers Squibb (EUA)
• Novo Nordisk A/S (Dinamarca)
• GSK Plc. (REINO UNIDO)
• AstraZeneca (Reino Unido)
• Cadila Pharmaceuticals (Índia)
• Sun Pharmaceutical Industries Ltd. (Índia)
• Amgen Inc.
• Abbott (EUA)
• Sunovion Pharmaceuticals Inc (EUA)
• Eisai Co., Ltd (Japão)
• Johnson & Johnson Private Limited (EUA)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (França)
• Bausch Health Companies Inc. (Canadá)
• H. Lundbeck A/S (Dinamarca)
• Marinus Pharmaceuticals, Inc (EUA)

SKU-63160